PMID- 19789507
OWN - NLM
STAT- MEDLINE
DCOM- 20100114
LR  - 20211203
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Linking)
VI  - 15
IP  - 10
DP  - 2009 Oct
TI  - Expression of mTOR protein and its clinical significance in endometrial cancer.
PG  - BR301-305
AB  - BACKGROUND: Mammalian target of rapamycin (mTOR) plays a crucial role in 
      carcinogenesis by regulating protein synthesis, and mTOR inhibitors have been 
      identified as potential anticancer agents in various cancers. Since the most 
      common genetic change in endometrial cancer is the mutation of phosphatase and 
      tensin homologue (PTEN), a negative regulator of mTOR, we evaluated mTOR 
      expression in endometrial cancer and its relationship with other 
      clinicopathological characteristics and expression patterns of cyclooxygenase-2 
      (COX-2) and p53. MATERIAL/METHODS: Immunohistochemical analysis of mTOR was 
      performed on paraffin-embedded tissue specimens obtained from 141 patients with 
      endometrial carcinoma. Results were correlated with the clinicopathological 
      characteristics and expression pattern of COX-2 and p53. RESULTS: mTOR 
      overexpression was detected in 7.1% (10/141) of patients. mTOR expression was 
      highly correlated with old age, menopausal status and COX-2 expression (P<0.05). 
      Multivariate analysis revealed that COX-2 was the only independent factor related 
      to expression of mTOR. However, there was no correlation of mTOR expression with 
      prognostic factors such as histologic type, grade, invasion of myometrium, lymph 
      node metastasis, stage, and survival. CONCLUSIONS: Our findings suggest that the 
      expression of mTOR is infrequent and is associated with COX-2 overexpression. 
      Careful selection of patients might be necessary in the use of mTOR inhibitor as 
      a molecular targeted therapy for patients with endometrial cancer.
FAU - No, Jae Hong
AU  - No JH
AD  - Department of Obstetrics and Gynecology, Seoul National University College of 
      Medicine, Seoul, Korea.
FAU - Jeon, Yong-Tark
AU  - Jeon YT
FAU - Park, In-Ae
AU  - Park IA
FAU - Kang, Daehee
AU  - Kang D
FAU - Kim, Jae Weon
AU  - Kim JW
FAU - Park, Noh-Hyun
AU  - Park NH
FAU - Kang, Soon-Beom
AU  - Kang SB
FAU - Song, Yong-Sang
AU  - Song YS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Aged
MH  - Cyclooxygenase 2/metabolism
MH  - Endometrial Neoplasms/*enzymology/pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Protein Kinases/*metabolism
MH  - TOR Serine-Threonine Kinases
MH  - Tumor Suppressor Protein p53/metabolism
EDAT- 2009/10/01 06:00
MHDA- 2010/01/15 06:00
CRDT- 2009/10/01 06:00
PHST- 2009/10/01 06:00 [entrez]
PHST- 2009/10/01 06:00 [pubmed]
PHST- 2010/01/15 06:00 [medline]
AID - 878209 [pii]
PST - ppublish
SO  - Med Sci Monit. 2009 Oct;15(10):BR301-305.